Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application, Desonide Cream, 0.05%.
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to market Silodosin Capsules, 4 mg and 8 mg.
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application, Diclofenac Sodium Topical Solution USP, 2% w/w.
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.